For comments, suggestions
Created with Raphaël 2.1.0 05.01.2016 Filing date 09.08.2017 Validation fee payment 28.02.2018 (A1) Patent application published 08.10.2019 AGEPI application filing date 30.11.2019 (T2) Translation of the validated European patent 06.06.2025 05.01.2026 Valid until 06.01.2027 Renewal fee to be paid until 05.01.2036 Patent will expire on

Patent in force


(210)Number of the EPO application16703620
(220)Filing date of the EPO application2016.01.05
(80)EPO patent specification publication (B)EPB nr. 33/2019, 2019.08.14
(110)EPO patent number3242887
(11)Number of the documentMD 3242887 T2
(21)Number of the applicatione 2017 0269
(71)Name(s) of applicant(s), code of the countryELI LILLY AND COMPANY, US;
(72)Name(s) of inventor(s), code of the countryALSINA-FERNANDEZ Jorge, US;
BOKVIST Bengt Krister, US;
COSKUN Tamer, US;
CUMMINS Robert Chadwick, US;
(73)Name(s) of owner(s), code of the countryELI LILLY AND COMPANY, US;
(54)Title of the inventionGIP and GLP-1 co-agonist compounds
(13)Kind-of-document code T2
(51)International Patent Classification C07K 14/575 (2006.01.01); C07K 14/605 (2006.01.01); A61K 38/26 (2006.01.01)
(19)CountryUS
(41)Date of publication of the application2018.02.28
(49)Date of publication of the translation of the validated European patent specification2019.11.30
(30)Priority201562101488 P, 2015.01.09, US
(74)Patent attorney(Procedură) PARASCA Dumitru, str. Eminescu nr. 40, ap. 13, c/p 28, MD-2012, Chişinău, Republica Moldova
(86)International applicationPCT/US2016/012124, 2016.01.05
(87)International publicationWO 2016/111971, 2016.07.14
Up
/Inventions/details/3242887